Cadence Pharmaceuticals, (FRA:QEW) EV-to-EBIT : -59.60 (As of Jun. 22, 2024)

Cadence Pharmaceuticals, EV-to-EBIT Chart

Cadence Pharmaceuticals, Annual Data
	Trend	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13
EV-to-EBIT		Get a 7-Day Free Trial					-9.27	-6.76	-2.70	-4.92	-27.47

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
EV-to-EBIT	Get a 7-Day Free Trial															-4.92	-8.54	-10.36	-11.53	-27.47

Competitive Comparison of Cadence Pharmaceuticals,'s EV-to-EBIT

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadence Pharmaceuticals,'s EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s EV-to-EBIT falls into.

Cadence Pharmaceuticals, EV-to-EBIT Calculation

Cadence Pharmaceuticals,'s EV-to-EBIT for today is calculated as:

Cadence Pharmaceuticals,'s current Enterprise Value is €887.38 Mil.
Cadence Pharmaceuticals,'s EBIT for the trailing twelve months (TTM) ended in Dec. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadence Pharmaceuticals,  (FRA:QEW) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cadence Pharmaceuticals,'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2013 is calculated as:

Cadence Pharmaceuticals,'s Enterprise Value for the quarter that ended in Dec. 2013 was €590.09 Mil.
Cadence Pharmaceuticals,'s EBIT for the trailing twelve months (TTM) ended in Dec. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadence Pharmaceuticals, EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, (FRA:QEW) Business Description